Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Tiziana Life Sciences Ltd.

< Previous 1 2 3 Next >
Tiziana Life Sciences to Host KOL Webinar on Foralumab in Non-Active Secondary Progressive Multiple Sclerosis (SPMS)
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
Tiziana Life Sciences Announces Participation on the Webull Corporate Communications Service Platform
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
Tiziana Life Sciences Announces Chief Medical Officer Invited to Give Presentation on Intranasal Foralumab on May 17
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
Tiziana Life Sciences Announces Findings from Intranasal Anti-CD3 mAb Treatment in Intracerebral Hemorrhage at the Annual American Academy of Neurology Conference
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
Tiziana Life Sciences Ltd Reports Annual Results for the Twelve Months Ended December 31, 2022, and Corporate Update
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
Tiziana Life Sciences Ltd. Regains Compliance with Nasdaq Listing Minimum Bid Price Rule
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
Tiziana Life Sciences to File Alzheimer’s IND for Intranasal Foralumab in Q2 2023
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
Tiziana Life Sciences Initiates Program to Develop Intranasal Foralumab in Type 1 Diabetes
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
Tiziana Life Sciences to Pursue Development of Intranasal Foralumab for the Treatment of Long COVID
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
Tiziana Life Sciences Announces Presentations on Intranasal Foralumab at the “Preserving the Brain” Scientific Conference and Exhibit at Prada Rong Zhai in Shanghai
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
Tiziana Life Sciences Announces Invitation for Podium Presentation of Research on Intranasal Anti-CD3 mAb in Intracerebral Hemorrhage at the Annual American Academy of Neurology Conference
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
Tiziana Announces Positive Data on Intranasal Anti-CD3 Monoclonal Antibody in Intracerebral Hemorrhage
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
Tiziana Life Sciences Announces Anti-CD3 mAb Research for the Treatment of Alzheimer’s Disease to be Presented by Dr. Howard Weiner at the International Conference on Alzheimer’s and Parkinson’s Disease and Related Neurological Disorders Conference in
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
Tiziana Life Sciences to Proceed with Phase 2 Clinical Trial in Patients with Non-Active Secondary Progressive Multiple Sclerosis (SPMS)
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
Tiziana Life Sciences Announces Purchase of Common Shares by Chairman and Acting CEO
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
Tiziana Life Sciences Announces Purchase of Common Shares by Chairman and Acting CEO
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
Tiziana Life Sciences Announces Purchase of Common Shares by Chairman and Acting CEO
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
Tiziana Life Sciences Announces Purchase of Common Shares by Chairman and Acting CEO
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
Tiziana Life Sciences Highlighted in Forbes Article
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
Tiziana Life Sciences Announces Publication in Proceedings of the National Academy of Sciences (PNAS) Illustrating the Immunological Basis of the Mechanism of Action for Intranasal Foralumab
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
Tiziana Life Sciences Announces IND filed for Phase 2 Study of Milciclib in Combination with Gemcitabine for Non-Small Cell Lung Cancer
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
Tiziana Life Sciences Announces Additional Clinical Improvements in the Second Patient with Non-Active Secondary Progressive Multiple Sclerosis (SPMS) After Eleven Months of Dosing with Intranasal Foralumab
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
Tiziana Life Sciences Ltd (“Tiziana” or “the Company”) - Updated Interim Results for the Six Months Ended 30 June 2022
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
Tiziana Life Sciences Ltd (“Tiziana” or “the Company”) - Interim Results for the Six Months Ended 30 June 2022
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
Tiziana to Participate in January Investor Meetings
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
Tiziana Life Sciences Announces Completion of Prerequisite Pre-Clinical Safety Study
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
Tiziana Life Sciences Ltd. Granted 180-day Extension by Nasdaq to Meet Minimum Bid Price Requirements
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
Tiziana Life Sciences Announces Date of Annual General Meeting 2022
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
Tiziana Announces Publication of a Peer-Reviewed Article on the Intranasal Administration of Foralumab Demonstrating Modulated Effector CD8+ T cell Function and an Induced T Cell Regulatory Response in Human Subjects
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
Tiziana Life Sciences Announces Near-Term Strategic Focus on Intranasal Foralumab for Diseases of the Central Nervous System (CNS)
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.